Immunome
IMNM
19.10
-0.22
-1.11%
Immunome
US · IMNM
#2671 by market cap
Listed 2020
19.10
-0.22
-1.11%
Live - 5344 symbols - heartbeat 42s ago
· 2026-10-08 06:54
Pre-market
19.00
-0.50%
After-hours
19.10
0.00%
- Market cap
- 2.25B
- P/E (TTM)i
- -7.55
- P/Bi
- 4.29
- EPSi
- -2.43
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on IMNM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 0.2 percentage points.
Institutional ownership
- Held by institutions
- 110.93% -0.16pp
- Institutions
- 248
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund86.33%
Hedge Fund11.25%
VC/PE Fund4.59%
Public Company4.50%
Private Company3.74%
Individual/Insider1.15%
Government Pension Fund0.31%
Insurance Company0.12%
Top holders as of 2026-06-30
T. Rowe Price Group, Inc.
18.89% · 21.45M sh
FMR
14.96% · 16.99M sh
BlackRock
7.75% · 8.81M sh
State Street Global Advisors
4.84% · 5.49M sh
Vanguard Capital Management, LLC
4.67% · 5.31M sh
Wellington Management Group
4.59% · 5.21M sh
Redmile Group, LLC
4.32% · 4.91M sh
Sirenia Capital Management LP
4.25% · 4.83M sh
PRIMECAP Management Company
4.03% · 4.58M sh
Driehaus Capital Management LLC
3.83% · 4.35M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 19 sells
| Name | Role | Stake |
|---|---|---|
| Clay Siegall | Chairperson & CEO | 0.61% |
| Philip Wagenheim | Director | 0.30% |
| Isaac Barchas | Lead Independent Director | 0.08% |
| Max Rosett | Officer | 0.05% |
| Jean-Jacques Bienaime | Director | 0.04% |
| Philip Tsai | Chief Technology Officer | 0.04% |
| Jack Higgins | Chief Scientific Officer | 0.02% |
| Robert Lechleider | Chief Medical Officer | 0.01% |
| Sandra Stoneman | Chief Legal Officer | 0.00% |
| James Boylan | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-10 | Jack Higgins | Chief Scientific Officer | Other Disposition | -4,000 | -- |
| 2026-09-10 | Jack Higgins | Chief Scientific Officer | Derivative Exercise and Sale | -18,000 | $1.35–25.32 |
| 2026-08-11 | Isaac Barchas | Lead Independent Director | Automatic Disposition | -11,048 | $27.25 |
| 2026-08-03 | Kinney Horn | Chief Business Officer | Derivative Exercise and Sale | -90,616 | $10.60–25.09 |
| 2026-07-22 | Clay Siegall | Chairperson & CEO | Other Acquisition | +180,000 | -- |
| 2026-07-22 | Clay Siegall | Chairperson & CEO | Other Derivative Acquisition | +360,000 | $22.01 |
| 2026-07-22 | Jack Higgins | Chief Scientific Officer | Other Acquisition | +38,250 | -- |
| 2026-07-22 | Jack Higgins | Chief Scientific Officer | Other Derivative Acquisition | +76,500 | $22.01 |
| 2026-07-22 | Robert Lechleider | Chief Medical Officer | Other Acquisition | +54,000 | -- |
| 2026-07-22 | Robert Lechleider | Chief Medical Officer | Other Derivative Acquisition | +108,000 | $22.01 |
| 2026-07-22 | Sandra Stoneman | Chief Legal Officer | Other Acquisition | +38,250 | -- |
| 2026-07-22 | Sandra Stoneman | Chief Legal Officer | Other Derivative Acquisition | +76,500 | $22.01 |
| 2026-07-22 | Kinney Horn | Chief Business Officer | Other Acquisition | +31,250 | -- |
| 2026-07-22 | Kinney Horn | Chief Business Officer | Other Derivative Acquisition | +62,500 | $22.01 |
| 2026-07-22 | Max Rosett | Officer | Other Acquisition | +47,250 | -- |
| 2026-07-22 | Max Rosett | Officer | Other Derivative Acquisition | +94,500 | $22.01 |
| 2026-07-22 | Philip Tsai | Chief Technology Officer | Other Acquisition | +38,250 | -- |
| 2026-07-22 | Philip Tsai | Chief Technology Officer | Other Derivative Acquisition | +76,500 | $22.01 |
| 2026-07-06 | Kinney Horn | Chief Business Officer | Derivative Exercise and Sale | -1,092 | $12.92–25.00 |
| 2026-07-01 | Robert Lechleider | Chief Medical Officer | Derivative Exercise and Sale | -55,000 | $8.73–23.44 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:54:41 · For reference only, not investment advice and not tailored to your situation.